Collagenase Clostridium Histolyticum for Refractory Iatrogenic Esophageal Strictures
Local Injection of Collagenase Clostridium Histolyticum (XiapexR) for Refractory Iatrogenic Esophageal Strictures: an Open-label Pilot Study
Sponsor: University Hospital, Ghent
Terminated
unexpected serious adverse event
Other terminated trials from University Hospital, Ghent
Listed as NCT03898661, this EARLY_PHASE1 trial focuses on Anastomotic and Collagenosis and remains terminated or withdrawn. Sponsored by University Hospital, Ghent, it has been updated 6 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated EARLY_PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Terminated EARLY_PHASE1
Status: Unknown Status → Terminated
-
Oct 2021 — Oct 2023 [monthly]
Unknown Status EARLY_PHASE1
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting EARLY_PHASE1
▶ Show 1 earlier version
-
May 2019 — Jan 2021 [monthly]
Recruiting EARLY_PHASE1
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Ghent
For direct contact, visit the study record on ClinicalTrials.gov .